ADVERTISEMENT

Testosterone treatment for hypogonadism does not boost short-term cardiovascular risk

Jenny Blair, MD   |   Clinical Summary   |   16 June 2022
ADVERTISEMENT

Takeaway

  • In men with hypogonadism, short-term testosterone treatment does not appear to increase cardiovascular or cerebrovascular event risk.
  • Longer-term effects, if any, are unknown.
  • Editorial advises waiting for 5-year TRAVERSE trial results before widespread testosterone therapy adoption.

Why this matters

  • Testosterone has a variety of potentially contrasting influences on cardiovascular...

          

January Challenge

Ends in 2d 14h
left
right

Topic Challenges

left
right